Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Health Economics
Most Women Not Willing to Pay for Genetic Breast Cancer Testing
By
Caroline Helwick
Economics & Value
,
Health Economics
February 2013, Vol 4, No 2
Direct-to-consumer (DTC) genetic testing using single nucleotide polymorphisms (SNPs) is of interest to women who are concerned about breast cancer; however, these women are unwilling to pay the current costs, researchers from the Department of Surgery and Institute for Health Policy Studies, University of California, San Francisco (UCSF), Medical Center, reported at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
Costs of Second-Line Metastatic Colorectal Cancer Treatments Compared
By
Caroline Helwick
Economics & Value
,
Health Economics
February 2013, Vol 4, No 2
San Francisco, CA—For the second- line treatment of patients with metastatic colorectal cancer (CRC), the total costs were 14% lower with bevacizumab (Avastin) than with cetuximab (Erbitux), according to an analysis presented at the 2013 Gastrointestinal Cancers Symposium.
Read Article
Cost-Effectiveness of MRI Screening in Women with Familial Breast Cancer Risk
Economics & Value
,
Health Economics
February 2013, Vol 4, No 2
San Antonio, TX—Adding magnetic resonance imaging (MRI) to a breast cancer screening strategy for women with a familial risk of cancer costs approximately 2.6 times as much per life-years gained compared with screening with mammography alone, Dutch researchers reported at the CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
Genetic Testing with Oncotype DX for Women with DCIS Shown Cost-Effective in Independent Study
Health Economics
January 2013, Vol 4, No 1
San Antonio, TX—In determining the optimal treatment of ductal carcinoma in situ (DCIS), gene expression profiling using the Oncotype DX DCIS Score is more cost-effective than standard clinical assessment, primarily because it avoids radiotherapy for approximately 66% of these patients.
Read Article
Azacitidine Reduces Transfusions and Costs for Patients with High-Risk MDS
By
Caroline Helwick
Health Economics
January 2013, Vol 4, No 1
Atlanta, GA—The use of azacitidine (Vidaza) in patients with high-risk myelodysplastic syndrome (MDS) is associated with the reduced need for red blood cell (RBC) transfusion and transfusion dependence, a report from the 2012 American Society of Hematology meeting showed.
Read Article
Cost of Screening Mammography Varies by Strategy
By
Caroline Helwick
Health Economics
January 2013, Vol 4, No 1
San Antonio, TX—The national cost of screening mammography could vary by as much as $7 billion annually, depending on the screening strategy, according to a new study reported at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article
Global Fees, ACOs, and New Reimbursement Trends Will Influence Medicare’s Future
Health Economics
July 2011, Vol 2, No 4
Growth in Medicare Part B spending, increasing roles in specialty pharmacy, formation of accountable care organizations (ACOs), and bundling of payments for care are all anticipated trends in the Medicare and reimbursement arenas.
Read Article
Reimbursement for Expensive Cancer Therapies: The Role of Cost-effectiveness Analysis
By
Gary C. Yee, PharmD, FCCP, BCOP
Economics & Value
,
Health Economics
May 2010, Vol 1, No 1
Due to changes in the US Food and Drug Administration (FDA) approval process for cancer drugs, many new cancer drugs have been approved over the past 10 to 15 years. Although the availability of these new drugs has improved survival for many cancer patients, there is increasing concern over the cost of these agents.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma